Compare NKTR & HUN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NKTR | HUN |
|---|---|---|
| Founded | 1990 | 1970 |
| Country | United States | United States |
| Employees | N/A | 6000 |
| Industry | Biotechnology: Pharmaceutical Preparations | Major Chemicals |
| Sector | Health Care | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.2B | 2.1B |
| IPO Year | 1996 | 2004 |
| Metric | NKTR | HUN |
|---|---|---|
| Price | $71.44 | $11.94 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 7 | 11 |
| Target Price | ★ $146.67 | $12.09 |
| AVG Volume (30 Days) | 833.2K | ★ 3.9M |
| Earning Date | 05-07-2026 | 04-30-2026 |
| Dividend Yield | N/A | ★ 2.64% |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | $307,711,000.00 | ★ $5,683,000,000.00 |
| Revenue This Year | N/A | $3.08 |
| Revenue Next Year | N/A | $5.27 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 86.00 | N/A |
| 52 Week Low | $21.02 | $7.30 |
| 52 Week High | $109.00 | $16.09 |
| Indicator | NKTR | HUN |
|---|---|---|
| Relative Strength Index (RSI) | 54.99 | 47.93 |
| Support Level | $64.28 | $10.45 |
| Resistance Level | $76.78 | $12.41 |
| Average True Range (ATR) | 3.57 | 0.56 |
| MACD | 0.17 | 0.09 |
| Stochastic Oscillator | 66.12 | 43.53 |
Nektar Therapeutics is a clinical-stage, research-based biopharmaceutical company headquartered in San Francisco, California, and incorporated in Delaware, focused on discovering and developing medicines in the field of immunotherapy. The Company directs its efforts toward creating immunomodulatory agents that selectively induce, amplify, attenuate, or prevent immune responses to achieve desired therapeutic outcomes. Its pipeline of clinical-stage and preclinical-stage immunomodulatory agents targets the treatment of autoimmune diseases, including rezpegaldesleukin, NKTR-0165, NKTR-0166, and NKTR-422, as well as cancer, including NKTR-255.
Huntsman Corp is a USA-based manufacturer of differentiated organic chemical products. The product portfolio of the company comprises Methyl diphenyl diisocyanate (MDI), Amines, Maleic anhydride, and Epoxy-based polymer formulations. The company's products are used in adhesives, aerospace, automotive, and construction products, and others. Its operating segments are Polyurethanes, Performance Products, and Advanced Materials. The company derives the majority of its revenue from the Polyurethanes segment, which includes MDI, polyols, TPU (thermoplastic polyurethane), and other polyurethane-related products. Its geographical segments are the United States & Canada, Europe, Asia-Pacific, and the Rest of the world.